We’re back live from the Bullpen “Money Ball” showcase at BIO International 2025 in Boston—and this one dives deep into a quiet crisis in drug development.
Our guest, Chandima Bandara, CEO of Precision Quantomics, is tackling one of the industry’s toughest stats: 90% of drugs fail before reaching patients—and half of those due to toxicity. His company is flipping the script by bringing quantitative proteomics into preclinical workflows, enabling smarter, earlier decisions before costly trials even begin.
This isn’t just about new tools—it’s about changing the mindset:
- Why LC-MS/MS might be the missing layer in drug development
- How small companies are building what Big Pharma won’t
- What happens when you democratize access to deep science
- And why Bullpen’s “Money Ball” is redefining how biotech founders show up and scale
